HPS Pharmacies wish to advise that Gilead Sciences Pty Ltd is currently experiencing a supply shortage of:
Vistide® (cidofovir) injection 375mg/5mL, Aust R 63050.
Production of Vistide® has been temporarily halted during an investigation of particulate matter identified in a batch which was only distributed outside Australia.
Gilead has no supplies of Vistide® available to replace stock currently in circulation, and healthcare professionals are advised to select alternative treatment options until availability returns to normal.
Supplies of Vistide® (cidofovir) injection 375mg/5mL currently available in Australia are safe to use.
Vistide® is indicated for the treatment of CMV retinitis in patients 12 years and over with acquired immunodeficiency syndrome (AIDS).
Please retain this notice in a prominent position, including other related business units, until supplies return to normal, and report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies or Gilead Sciences Pty Ltd Medical Information on (03) 9272 4400.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.